HEALTHCARE PROFESSIONALS

Cost Saving

Save 50% of the cost of category C ropinirole prescriptions by prescribing Repinex XL.2*

By prescribing Repinex® XL by brand, the average savings for ICS/ICB’s could still be approximately £49,475 per year, providing the NHS with a total potential annual prescribing cost saving of approximately £2 million.1

Repinex XL is part of the cost-saving prolonged-release product range from Aspire Pharma.

  • Over 50% saving on cost of Category C Drug Tariff price;2*
  • Available from all mainline wholesalers;
  • High level of stockholdings;
  • Price Guaranteed***
  • Bioequivalent to the originator.3
ProductCategory C UK Drug Tariff priceRepinex XL price
Ropinirole prolonged-release tablets 2mg x 28 £12.54£6.20
Ropinirole prolonged-release tablets 4mg x 28 £25.09£12.50
Ropinirole prolonged-release tablets 8mg x 28 £42.11£21.00
*50% saving on the cost of Category C ropinirole prolonged-release tablets in the UK Drug Tariff. **Savings based on market data in reference 1 for 42 ICS/ICB’s switching their generic and brand originator 2,4 and 8mg ropinirole prolonged-release tablet prescriptions to Repinex XL. ***No change in price subject to no material change to the products or Category C of the UK Drug Tariff until the 2026 VPAG review.
References 1) Insypher 10100831045 v 17.0 January 2024 GPPLPD Date Range: Jul-23 – Sep-23  2) February 2024 UK Drug Tariff. 3) Data on file. 1010067149 v 6.0 September 2023.

TRUSTED BRANDS.
DEPENDABLE SUPPLY CHAIN.

For further information please call: 01730 231148,
email: [email protected] or visit www.aspirepharma.co.uk
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Aspire Pharma Ltd on 01730 231148

For more information about Repinex XL, please click here for the prescribing information.

Revision reference – Repinex XL_24_01.02.24

More products available
in this range:
Click to view their
individual websites